ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1281

Maintenance Therapy for anti-MDA5-Positive Dermatomyositis Patients with Interstitial Lung Disease: Can They Achieve Drug-Free Remission?

Tsuneo Sasai1, Ran Nanashima 1, Tsuneyo Mimori 2, Hideaki Tsuji 1, Shuji Akizuki 1, Kosaku Murakami 3, Motomu Hashimoto 3, Hajime Yoshifuji 1, Masao Tanaka 2 and Koichiro Ohmura 2, 1Kyoto University, Kyoto, Japan, 2Graduate School of Medicine, Kyoto University, Kyoto, Japan, 3Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Idiopathic Inflammatory Myopathies (IIM) and interstitial lung disease

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Session Title: Muscle Biology, Myositis & Myopathies Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) accompanied by anti-melanoma differentiation associated gene 5 (MDA5)-positive dermatomyositis (DM) is often rapidly progressive and associated with poor life prognosis in Japanese patients. Recently, combined immunosuppressive therapy such as high-dose glucocorticoid (GC), calcineurin inhibitor (CNI), and intravenous cyclophosphamide (IVCY) has been suggested to be so effective that the prognosis has been improved. However, after achieving remission, appropriate maintenance therapy is still unclear. In this study, we evaluated the effect of induction therapy on maintenance therapy and looked into the possibility of drug-free remission.

Methods: We retrospectively examined the medical records of 86 anti-MDA5-positive adult DM-ILD patients in Kyoto university hospital. There were 57 patients who had achieved remission and survived more than 6 months. According to the induction treatment, we classified into 3 groups, Group A (n=37); simultaneous triple combination therapy (GC, CNI and IVCY with all drugs started within a week), Group B (n=8); step-up triple combination therapy (initiation of IVCY delayed up to 3 month)) and Group C (n=12); mono/dual-therapy (GC with or without CNI). We compared the recurrence rates by using log-rank test. We also compared the maintenance dose of GC at 36 months since initial treatment and the rates of drug free patients.

Results: The recurrence rates of Group A, B and C were not significantly different (p=0.07, log-rank test). The recurrence rates at 36 months since initial treatment were 0%, 0%, 19%, respectively (Figure 1). The dose of GC in Group A, B and C were 3.4±2.2 vs 4.0±1.2 vs 6.3±2.2 mg/day, respectively (p< 0.05, Kruskal-Wallis test). Although the drug free rates from GC were not significantly different (13% vs 0% vs 0%, p=0.07, Figure 2), the CNI free rates of Group A were significantly higher than that of Group C (43% vs 0%, p< 0.01 with Bonferroni correction, Figure 3).

Conclusion: Triple combined immunosuppressants for induction therapy could reduce the maintenance dose of immunosuppressants and the risk of recurrence in anti-MDA5-positive DM-ILD. Moreover, initial combination therapy might lead some patients to achieve drug-free remission.

Figure 1. Relapse-free survival rates -Kaplan-Meier-

Figure 2. Drug free rates from Glucocorticoid

Figure 3. Drug free rates from Calcineurin inhibitor


Disclosure: T. Sasai, None; R. Nanashima, None; T. Mimori, None; H. Tsuji, None; S. Akizuki, None; K. Murakami, Astellas Pharma Inc., 8, Bristol Myers Squibb,, 8, Chugai Pharmaceutical Co. Ltd., 8, Daiichi Sankyo Co. Ltd., 8, Eisai Co. Ltd, 8, Mitsubishi Tanabe Pharma Corporation, 8, Pfizer Inc, 8, UCB Japan Co. Ltd, 8; M. Hashimoto, Astellas, 8, Ayum, 9, Brystol-Meyers, 8, Chugai, 9, Tanabe-Mitsubishi, 8, 9, UCB Japan, 9; H. Yoshifuji, Astellas Pharma, 2, Chugai Pharmaceutical, 8; M. Tanaka, None; K. Ohmura, None.

To cite this abstract in AMA style:

Sasai T, Nanashima R, Mimori T, Tsuji H, Akizuki S, Murakami K, Hashimoto M, Yoshifuji H, Tanaka M, Ohmura K. Maintenance Therapy for anti-MDA5-Positive Dermatomyositis Patients with Interstitial Lung Disease: Can They Achieve Drug-Free Remission? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/maintenance-therapy-for-anti-mda5-positive-dermatomyositis-patients-with-interstitial-lung-disease-can-they-achieve-drug-free-remission/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/maintenance-therapy-for-anti-mda5-positive-dermatomyositis-patients-with-interstitial-lung-disease-can-they-achieve-drug-free-remission/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences